Kausik Ray

Professor of Public Health

Imperial College London

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Kausik Ray is a Professor of Public Health at Imperial College London. His research focuses on cardiovascular disease, including the management of dyslipidaemias, the evaluation of lipid profiles, and patient perceptions in global health contexts. Recent articles highlight his involvement in studies concerning LDL cholesterol management and cardiac rehabilitation across various populations and settings.

Articles (23)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (15)

Kornelia Kotseva

National University of Ireland Galway

IRELAND

Kausik Ray

Research Interests

Explore related searches

Contact this professor

About

Articles (23)

Factors Associated with Elevated High-Sensitivity C-Reactive Protein Levels in Individuals with Atherosclerotic Cardiovascular Disease in the US and the UK

Cardiac rehabilitation in patients with coronary heart disease - provision, attendance, and outcomes: results from the INTERASPIRE survey from fourteen countries across six WHO regions

Patient perceptions on lipoprotein(a) testing and treatment for secondary prevention of cardiovascular disease: results from the INTERASPIRE study in seven countries across five World Health Organization regions

Characterization of lipidic plaque features in association with LDL-C<70 mg/dL and lipoprotein(a) <50 mg/dL

Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials

Intensive early and sustained lowering of non–high-density lipoprotein cholesterol after myocardial infarction and prognosis: the SWEDEHEART registry

Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION‐9, ORION‐10 and ORION‐11 Phase 3 randomized trials

Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias–A report from the European Society of Cardiology Cardiovascular Round Table

Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study

Estimating potential cardiovascular health benefits of improved population level control of LDL cholesterol through a twice-yearly siRNA-based approach: A simulation study of a health-system level intervention

Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study

LDL-cholesterol goal attainment with ezetimibe and bempedoic acid in patients at high and very-high cardiovascular risk: A simulation study in the Italian cohort of the SANTORINI study

Lipid-lowering treatment and LDL-C goal attainment in high and very high cardiovascular risk patients: Evidence from the SANTORINI study-The Italian experience

Inclisiran and cardiovascular events: a patient-level analysis of phase III trials

Novel and future lipid-modulating therapies for the prevention of cardiovascular disease

Optimal implementation of the 2019 ESC/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study

Evolocumab effectiveness in the real-world setting: Austrian data from the pan-European observational HEYMANS study

The global diagnostic network: what can we learn from half a billion lipid measurements between 2018 and 2020?

Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial

Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: Final results from the European observational HEYMANS study

What about glucagon-like peptide-1 receptor agonist for all? Recent data and perspectives

Collaborators (15)

Kornelia Kotseva

timo strandberg

Wolfgang Koenig

Naveed Sattar

David Thompson

Jonas Brinck

Carmine Izzo

John McEvoy

Piotr Jankowski

Fu Siong Ng

Jaimini Cegla

Hermann Toplak

Alberico Luigi Catapano

Paolo Calabrò

Anna Solini

Make your next move.